MANNKIND CORP Interest Payable, Current
MANNKIND CORP (MNKD) had Interest Payable, Current of $10.98 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2026-08-05
- 2026-06-30: Interest Payable, Current $10.98M.
- 2026-03-31: Interest Payable, Current $1.82M.
- 2025-12-31: Interest Payable, Current $2.15M.
- 2025-09-30: Interest Payable, Current $1.11M.
| Period end | Interest Payable, Current |
|---|---|
| 2026-06-30 | $10.98M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.82M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.15M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $303.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.44M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $303.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $479.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $6.17M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $680.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.15M 10-K · filed 2025-02-26 |
| 2023-09-30 | $743.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $6.27M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $763.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.20M 10-K · filed 2024-02-27 |
| 2022-09-30 | $754.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $6.07M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $729.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.17M 10-K · filed 2023-02-23 |
| 2021-09-30 | $721.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.13M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $4.49M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $519.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $350.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $410.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $337.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $409.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $319.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $733.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $494.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $492.00K 10-K · filed 2020-02-25 |
| 2018-09-30 | $767.00K 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.50M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $226.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $567.00K 10-K · filed 2019-02-26 |
| 2017-09-30 | $234.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $624.00K 10-Q · filed 2017-08-07 |
| 2017-03-31 | $221.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $619.00K 10-K · filed 2018-02-27 |
| 2016-09-30 | $212.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $602.00K 10-Q/A · filed 2016-08-10 |
| 2016-03-31 | $199.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | $615.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $473.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $2.40M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $1.02M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $2.40M 10-K · filed 2016-03-15 |
| 2014-09-30 | $958.00K 10-Q · filed 2014-11-10 |
| 2014-06-30 | $2.40M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $958.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $2.08M 10-K · filed 2015-03-02 |
| 2013-09-30 | $3.27M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $7.91M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $5.86M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $4.53M 10-K · filed 2014-03-03 |
| 2012-09-30 | $4.35M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $2.46M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $8.26M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |